LAVA Therapeutics
Biotechnology Research • 
Utrecht, Utrecht, Netherlands • 21-50 Employees
Company overview
| Headquarters | Yalelaan 60, 5th floor, Utrecht, Utrecht 3584 CM, NL |
| Phone number | +31850657344 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Keywords | Biotechnology, Oncology, Bispecific Antibodies, Gamma Delta T Cells |
| Founded | 2016 |
| Employees | 21-50 |
| Socials |
Key Contacts at LAVA Therapeutics
Stephen Hurly
Ceo & President
Robert Tobia
Director, Fp&A And Sec Reporting
Priya Malini
Senior Director
Jurjen Ruben
Associate Director Bioanalytics
Ashwini Kulkarni
Associate Director Regulatory Cmc
Victoria Iglesias
Associate Director Preclinical
Pauline Van Helden
Director Translational Research
Thilo Riedl
Senior Director Bioanalytical Assays
Jurjen Ruben
Associate Director
LAVA Therapeutics Email Formats
LAVA Therapeutics uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@lavatherapeutics.com), used 80% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@lavatherapeutics.com | 80% |
{first name}.{last name} | john.doe@lavatherapeutics.com | 20% |
About LAVA Therapeutics
At LAVA, we are focused on applying our expertise in gamma-delta T-cell engagers (TCEs) to transform cancer therapy. We refer to our compounds as gamma-delta bispecific T-cell engagers, or gamma-delta bsTCEs. Our platform generates therapeutics that specifically activate a unique and relatively abundant effector gamma-delta T-cell subset called Vγ9Vδ2 (Vgamma9-Vdelta2) T-cells that have the ability to trigger activity of immune cells of both the innate and adaptive immune system. Our gamma-delta bsTCEs have demonstrated superior efficacy and safety profiles compared to other bsTCE approaches in preclinical studies and show preferential activity against tumor cells thereby potentially limiting toxicity in healthy tissue. To date, we are the only company developing bispecific gamma-delta T-cell engaging antibodies for the treatment of cancer. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor specific antigen CD1d, which can be overexpressed in multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML), among other tumor types. LAVA-051 will enter a Phase I/IIa study in 1Q21.
LAVA Therapeutics revenue & valuation
| Annual revenue | $31,200,000 |
| Revenue per employee | $1,073,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $99,600,000 |
| Total funding | $83,000,000 |
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
LAVA Therapeutics has 14 employees across 8 departments.
Departments
Number of employees
LAVA Therapeutics Tech Stack
Discover the technologies and tools that power LAVA Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Web servers
Performance
JavaScript libraries
Tag managers
Webmail
Programming languages
Security
Miscellaneous
Video players
Blogs
Analytics
Maps
Spain
China
Brazil
Frequently asked questions
4.8
40,000 users
